Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

76618

registered interest
date	09/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neurofibromatosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to develop a national service framework for neurofibromatosis Type 1 sufferers.
tabling member printed	Lord Hunt of Kings Heath
uin	HL960
answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL961 HL962 question first answered 14/07/2014 16:18:37 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76619

registered interest
date	09/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neurofibromatosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how they will ensure a co-ordinated response at local level for neurofibromatosis Type 1 sufferers.
tabling member printed	Lord Hunt of Kings Heath
uin	HL961
answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL960 HL962 question first answered 14/07/2014 16:18:38 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76620

registered interest
date	09/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neurofibromatosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what is the scale of neurofibromatosis Type 1 in the United Kingdom.
tabling member printed	Lord Hunt of Kings Heath
uin	HL962
answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL960 HL961 question first answered 14/07/2014 16:18:38 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76608

registered interest
date	08/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services and Social Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what was the combined spending on health and social care in the financial year 2013–14.
tabling member printed	Lord Stoddart of Swindon
uin	HL952
answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>Provisional spending outturn figures for all government departments will be published in HM Treasury's Public Expenditure Statistical Analyses on the 15 July.</p><p> </p><p>For the Department this will include a provisional total spending forecast against the Total Departmental Expenditure Limit control of £109,721 million.</p><p> </p><p>Final spending outturn figures will be published in the 2013-14 Department of Health Annual Report and Accounts, due to be laid to Parliament in July 2014.</p><p> </p> answering member printed Earl Howe question first answered 14/07/2014 12:58:52 answering member 2000 label Biography information for Earl Howe
tabling member	950 label Biography information for Lord Stoddart of Swindon

65817

registered interest
date	03/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	In Vitro Fertilisation
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Viscount Younger of Leckie on 28 January 2013 (WA 269), what conclusions were reached by the Human Fertilisation and Embryology Authority's small panel regarding assessment of the effects of pronuclear transfer on tissues with different energetic requirements or numbers of mitochondria; whether it was ultimately evaluated using stem cell lines from the reconstructed embryos or by induced pluripotent stem cells; whether the relevant findings were published in peer-reviewed journals; and, if so, which.
tabling member printed	Lord Alton of Liverpool
uin	HL809
answer	answer is ministerial correction date of answer 17/07/2014 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that the conclusions reached by the Expert Panel on this issue are outlined in its reports of April 2011, March 2013 and June 2014, which can be found on the HFEA's website at:</p><p> </p><p>www.hfea.gov.uk/6896.html</p><p> </p><p>Section 4.9 of the 2014 report outlines the panel's recommendation for research in this area and Annex B details the evidence reviewed. This can be found on the HFEA's website at:</p><p> </p><p><a href="http://www.hfea.gov.uk/8807.html" target="_blank">www.hfea.gov.uk/8807.html</a></p><p> </p> answering member printed Earl Howe question first answered 17/07/2014 11:47:12 answering member 2000 label Biography information for Earl Howe
tabling member	738 label Biography information for Lord Alton of Liverpool

65841

registered interest
date	03/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how much rebate they have so far received from pharmaceutical companies under the new Pharmaceutical Price Regulation Scheme agreement.
tabling member printed	Lord Hunt of Kings Heath
uin	HL833
answer	answer is ministerial correction date of answer 09/07/2014 answer text <p>The Department has received £74 million from members of the Pharmaceutical Price Regulation Scheme (PPRS) in respect of PPRS payments for the first quarter of the calendar year 2014. The Department intends to publish aggregate information on sales reports and payments made under the scheme on a quarterly basis. The first such publication was made on 30 June and can be found on the Government's website at:</p><p> </p><p>www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information</p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the Mandate and as such were included within commissioner allocations.</p><p> </p><p>The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines. As part of implementing the PPRS, NHS England and the Association of the British Pharmaceutical Industry are discussing how best to improve access to, and optimise patient outcomes from, these medicines.</p> answering member printed Earl Howe grouped question UIN HL834 HL835 question first answered 09/07/2014 15:18:03 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

65842

registered interest
date	03/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether the rebate they receive from pharmaceutical companies under the new Pharmaceutical Price Regulation Scheme agreement will be reallocated as an additional resource to the National Health Service.
tabling member printed	Lord Hunt of Kings Heath
uin	HL834
answer	answer is ministerial correction date of answer 09/07/2014 answer text <p>The Department has received £74 million from members of the Pharmaceutical Price Regulation Scheme (PPRS) in respect of PPRS payments for the first quarter of the calendar year 2014. The Department intends to publish aggregate information on sales reports and payments made under the scheme on a quarterly basis. The first such publication was made on 30 June and can be found on the Government's website at:</p><p> </p><p>www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information</p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the Mandate and as such were included within commissioner allocations.</p><p> </p><p>The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines. As part of implementing the PPRS, NHS England and the Association of the British Pharmaceutical Industry are discussing how best to improve access to, and optimise patient outcomes from, these medicines.</p> answering member printed Earl Howe grouped question UIN HL833 HL835 question first answered 09/07/2014 15:18:04 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

65843

registered interest
date	03/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government to what extent they propose to use the rebate they expect to receive from pharmaceutical companies under the new Pharmaceutical Price Regulation Scheme agreement to invest in innovative new medicines and procedures.
tabling member printed	Lord Hunt of Kings Heath
uin	HL835
answer	answer is ministerial correction date of answer 09/07/2014 answer text <p>The Department has received £74 million from members of the Pharmaceutical Price Regulation Scheme (PPRS) in respect of PPRS payments for the first quarter of the calendar year 2014. The Department intends to publish aggregate information on sales reports and payments made under the scheme on a quarterly basis. The first such publication was made on 30 June and can be found on the Government's website at:</p><p> </p><p>www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information</p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the Mandate and as such were included within commissioner allocations.</p><p> </p><p>The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines. As part of implementing the PPRS, NHS England and the Association of the British Pharmaceutical Industry are discussing how best to improve access to, and optimise patient outcomes from, these medicines.</p> answering member printed Earl Howe grouped question UIN HL833 HL834 question first answered 09/07/2014 15:18:04 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

65846

registered interest
date	03/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Better Care Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans there are for each Health and Wellbeing Board to agree performance measures for implementing the Better Care Fund; and what progress has been made to date.
tabling member printed	Lord Kennedy of Southwark
uin	HL838
answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>Following a review of the first set of local plans for the Better Care Fund (BCF), it has become clear that while the majority of areas have made good progress, there is more we need to do to ensure every area is on track to deliver from next April.</p><p> </p><p>As part of this, Ministers have agreed revised arrangements for the pay for performance scheme to ensure that financial benefits linked to reductions in emergency admissions can be clearly demonstrated and that health services and councils share the financial responsibility if emergency admissions are not reduced.</p><p> </p><p>Key elements of the agreement are:</p><p> </p><p>- BCF performance payments will now be linked to reducing emergency admissions;</p><p>- the size of the performance payment will be determined by local decisions on the level of ambition for the reduction in emergency admissions and the amount spent on local NHS services, as set out in the plan agreed by the local Health and Wellbeing Board;</p><p>- the remaining money from the performance pot not earned through reducing emergency admissions will be used to support local NHS services, as agreed by Health and Wellbeing Boards; and</p><p>- the wider metrics in the initial performance framework will continue to be used to monitor progress, but will not be used in assessments for the pay for performance scheme.</p><p> </p><p>Revised guidance on the new pay for performance scheme and further information required to improve BCF plans will be provided to the sector in coming weeks, alongside details of support available and the timetable for submitting revised plans.</p> answering member printed Earl Howe question first answered 14/07/2014 16:17:46 answering member 2000 label Biography information for Earl Howe
tabling member	4153 label Biography information for Lord Kennedy of Southwark

65241

registered interest
date	02/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Folic Acid
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether the Department of Health expects soon to start discussions with the relevant food industry companies about their willingness in principle to stop voluntary fortification of food products with folic acid, if mandatory fortification were to be introduced; and, if so, when.
tabling member printed	Lord Rooker
uin	HL771
answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>Discussions with relevant food industry companies have begun. The Department is in the process of contacting organisations across a range of sectors and we hope to complete these discussions by the end of 2014.</p><p> </p><p>The Department is in the final stages of commissioning research to explore any new and innovative communication approaches that would be effective in raising awareness among women of the need to take folic acid supplements and in promoting behaviour change. This research is scheduled for completion in the first quarter of 2015.</p> answering member printed Earl Howe grouped question UIN HL772 question first answered 14/07/2014 16:14:06 answering member 2000 label Biography information for Earl Howe
tabling member	302 label Biography information for Lord Rooker